Please login to the form below

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Roche gets wider approval for haemophilia drug Hemlibra

Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla – with the advantage of being dosed every one, two, or four weeks depending on need, rather than multiple times

Latest news

Bayer roll-out of haemophilia drug Jivi gathers pace

and Eloctate, and CSL Behring’s Afstyla, uptake hasn’t been as quick as many had hoped, so Jivi is entering a challenging market.
Roche highlights Hemlibra data as key FDA date approaches

every few days, such as Shire’s Adynovate, Biogen’s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla, uptake hasn’t been as quick as hoped.
Roche’s Hemlibra first drug to top standard therapy in haemophilia A

well as Biogen’s Eloctate, Bayer’s Kovaltry and CSLBehring’s Afstyla.
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as
New data could unlock bigger market for Roche’s Hemlibra

Haemophilia A treatment is being transformed by a series of long-acting Factor VIII products such as Biogen’s Eloctate, Shire’s Adynovate, Bayer’s Kovaltry and CSLBehring’s Afstyla, which

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders. During 2016 Eloctate and Alprolix

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Manager / Account Director: Competative

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Medical Writer: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Global Business Development Director – Health Education: excellent commission

Account Director – Health Policy – Global Agency: Salary TBC

Associate Director: £75, 000-90, 000

Medical Writer: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...